Compounding Health Risks and Increased Vulnerability to SARS-Cov-2 for Racial and Ethnic Minorities and Low Socioeconomic Status Individuals in the United States
Total Page:16
File Type:pdf, Size:1020Kb
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 15 April 2020 doi:10.20944/preprints202004.0234.v1 Compounding Health Risks and Increased Vulnerability to SARS-CoV-2 for Racial and Ethnic Minorities and Low Socioeconomic Status Individuals in the United States Elise M. Myers1 [email protected] 1Columbia University; 535 W 116th Street, New York, NY 10027 Abstract Recent clinical SARS-CoV-2 studies link diabetes, cardiovascular disease, and hypertension to increased disease severity. In the US, racial and ethnic minorities and low socioeconomic status (SES) individuals are more likely to have increased rates of these comorbidities, lower baseline health, limited access to care, increased perceived discrimination, and limited resources, all of which increase their vulnerability to severe disease and poor health outcomes from SARS-CoV- 2. Previous studies demonstrated the disproportionate impact of pandemic and seasonal influenza on these populations, due to these risk factors. This paper reviews increased health risks and documented health disparities of racial and ethnic minorities and low SES individuals in the US. Pandemic response must prioritize these marginalized communities to minimize the negative, disproportionate impacts of SARS-CoV-2 on them and manage spread throughout the entire population. This paper concludes with recommendations applicable to healthcare facilities and public officials at various government levels. Keywords: Coronavirus, COVID-19, comorbidity, race and ethnicity, health disparities Introduction The novel human coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2 or COVID-19), was declared a pandemic by the WHO on March 11, 20201. Since the January 15th arrival of the first documented case in the United States, the disease has been rapidly spreading through the country, reaching every state and the District of Columbia (DC) by March 17th. As of April 8, 2020, there have been 554,849 confirmed cases and 21,942 deaths nationwide, with every state, DC, and 4 of 8 territories reporting cases2. Rising wealth inequality3 and persistent social disparities experienced by racial and ethnic minorities in the US4 lead to significant vulnerability of racial and ethnic minorities and low socioeconomic status (SES) individuals to pandemic events5. Already, there have been reports of disproportionate prevalence and severity of SARS-CoV-2 cases among Blacks6,7,8,9, and American Indians10*. Previous research has highlighted the disproportionate impact of the H1N1 Influenza A pandemic11,12,13,14,15 and seasonal influenza16,17,18 on both racial and ethnic minorities and low SES individuals. Existing disparities for racial and ethnic minorities and low SES individuals in the US, combined with evidence of disproportionate impacts of influenza, suggest that SARS-CoV-2 will have a devastating impact on these vulnerable populations. This articles reviews: 1) recent findings related to comorbidities and SARS-CoV-2 case severity, 2) disparities in health and healthcare © 2020 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 15 April 2020 doi:10.20944/preprints202004.0234.v1 for racial and ethnic minorities in the US, 3) health risks associated with lower SES, and 4) compounding risk at the intersection of low SES and racial and ethnic minority identity. To conclude, recommendations for minimizing the impact of the SARS-CoV-2 pandemic on vulnerable populations are provided for both inside healthcare facilities and at various community organization and government levels. SARS-CoV-2 Risks for Patients with Comorbidities From recently available data on patients from the early stages of the outbreak of SARS-CoV-2 in China, it is increasingly apparent that, in addition to older patients19, patients with comorbidities have a higher likelihood of severe disease and an increased risk of death20. Recent studies report a range of 40-63% of severely or critically ill hospitalized patients have comorbidities19,20,21,22,23, similar to ranges reported for Middle East Respiratory Syndrome coronavirus (MERS-CoV)24. Further, patients with severe disease are more likely to have a co-existing illness than patients with non-severe disease25. The most common comorbidities reported in these early studies are hypertension, diabetes mellitus, and cardiovascular disease19,21,25,26, all of which have been correlated to increased mortality risk19 and severe disease25 in SARS-CoV-2 patients. Pre-existing cardiovascular disease and diabetes previously have been linked to acute cardiac events and poor health outcomes for patients with influenza and respiratory infections27,28,29,30,31. One hypothesis for increased SARS-CoV-2 severity with hypertension and diabetes is that both conditions can be treated with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type-I receptor blockers (ARBs), which increase the expression of ACE232,33. Because human pathogenic coronaviruses bind to target cells via ACE 2, treatment of hypertension and diabetes with ACE inhibitors and ARBs could facilitate SARS-CoV-2 infection and increase disease severity34. Alternative treatments for patients with hypertension and diabetes that do not increase ACE 2 expression may be important to implement34. In addition, individual-specific treatment plans to address serious comorbidities alongside pneumonia have been recommended23. Chronic lung or respiratory system disease19,21,26, cerebrovascular disease21,25, chronic kidney disease19 and a history of smoking21 are other comorbidities reported in patients with more severe cases of SARS-CoV-2. Of these comorbidities, chronic lung disease and chronic kidney disease significantly correlate with increased mortality risk19. Notably missing from studies is concrete information on the effect of asthma on SARS-CoV-2 severity, which has been attributed to the low prevalence in the general population in China26. Generally, the presence of any comorbidity increased the risk of severe illness and mortality for SARS-CoV-2 hospitalized patients20,25,26. In one study, 23% of SARS-CoV-2 critically ill patients had aggravated disease that was attributed to their original comorbidity23. Previous work demonstrated that diabetes, hypertension, obesity, and cardiovascular disease correlate with case severity of other coronaviruses, including MERS-CoV24 and influenza illness35,36. Recent studies have also demonstrated that SARS-CoV-2 infections can cause damage to various organs (i.e. heart, liver, and kidneys) and organ systems (i.e. blood and immune)21,37. Damage to organs and organ systems that are already compromised by comorbidities likely contributes to the complication of organ system and organ failure19-22. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 15 April 2020 doi:10.20944/preprints202004.0234.v1 It is important to note that data from hospitalized patients does not reflect the total disease burden of the general population, in which an estimated 80% of total SARS-CoV-2 cases are likely mild38 and do not require hospitalization. However, data on hospitalized patients provides insight into which subpopulations are more vulnerable to severe disease and higher mortality risk. Elevated Risk for Severe SARS-CoV-2 for Racial and Ethnic Minorities in the United States Elevated Risks for Seasonal Influenza, Pneumonia, and Respiratory Infections Disparities in morbidity and mortality for racial and ethnic groups have been previously identified in respiratory diseases, including pneumonia and seasonal influenza39,40,41. The US has a long history of health disparities for seasonal and pandemic influenza, with higher mortality rates for Black vs. non-Hispanic white (NHW) populations reported from the 1918-1919 influenza pandemic42,43 through to modern day5,16,44. Hospitalization rates for Black and Hispanic children are higher than those of NHWs for respiratory syncytial virus, seasonal influenza, and parainfluenza viruses17. Further, rates of respiratory viral infections are higher for Apache Indians, Alaska Natives and Blacks than for NHWs45. These aforementioned differences align with the larger trend that influenza-associated pneumonia and pandemic influenza-related deaths are more common in racial and ethnic minority populations16,40,46,47. The increased risks to racial and ethnic minorities in the United State in the current SARS-CoV- 2 pandemic are similar to those highlighted during the 2009 H1N1 novel influenza A pandemic. An estimated 60.8 million cases of H1N1 with 274,304 hospitalizations and 12,469 deaths occurred in the US from April 2009 to April 201048. The current SARS-CoV-2 pandemic has caused more deaths in the US in under 3 months (21,942 deaths as of April 13, 20202), demonstrating the increased severity of the current pandemic and underlining the need to examine and apply past lessons to protect vulnerable populations. Severe cases of H1N1 in the United States were found to disproportionately impact racial and ethnic minorities, as noted through age-adjusted hospitalization rates and deaths11,12,49. Hospitalizations related to H1N1 were most common for American Indians and Alaska Natives12, though Hispanics and Blacks also were hospitalized at higher rates than NHWs12,49. In fact, American Indians were 2.6 times more likely to be hospitalized than NHWs13, while Alaska Native and Asian/Pacific Islanders were 2-4 times likely to be hospitalized than NHWs during the H1N1 pandemic14. Overall,